Recombinant Human Receptor-type tyrosine-protein phosphatase epsilon (PTPRE)

What is Receptor-type Tyrosine-protein Phosphatase Epsilon (PTPRE) and how was it discovered?

Receptor-type tyrosine-protein phosphatase epsilon (PTPRE) is a member of the protein tyrosine phosphatase family that regulates various cellular signaling pathways by removing phosphate groups from tyrosine residues in proteins. PTPRE was initially identified in 1990 through hybridization with a Drosophila phosphatase cDNA under non-stringent hybridization conditions. The discovery process involved using conserved phosphatase domains to identify new members of this enzyme family. Subsequently, the murine PTPRE gene was mapped to chromosome 7, while the human PTPRE gene was localized to chromosome 10q26 .

The discovery of PTPRE represented an important advancement in understanding phosphatase-mediated regulation of cellular signaling. Comparative sequence analysis revealed that human PTPRE shares 94% amino acid homology with its murine and rat counterparts, indicating a high degree of evolutionary conservation that suggests important functional roles across species . This conservation has enabled researchers to use rodent models to study PTPRE function with reasonable translational implications for human biology.

What are the key structural features of PTPRE and how do they relate to its function?

PTPRE exists in multiple isoforms, with membrane-bound (memPTPRE) and cytosolic (cytPTPRE) forms being the most extensively studied. The membrane-bound form contains an extracellular domain, a transmembrane region, and an intracellular catalytic domain responsible for phosphatase activity. The cytosolic form lacks the extracellular and transmembrane domains but retains the catalytic domain. Both isoforms share identical C-terminal regions containing the phosphatase domains that are critical for enzymatic function.

The structural features of PTPRE determine its subcellular localization and substrate accessibility, directly influencing its functional roles. The membrane-bound form primarily localizes to the plasma membrane where it can interact with membrane-associated or transmembrane substrates, while the cytosolic form can access cytoplasmic substrates. This differential localization allows PTPRE to regulate distinct signaling pathways depending on the cellular context. The catalytic domain contains a highly conserved active site with a cysteine residue essential for phosphatase activity, and mutations in this region significantly impact PTPRE function in experimental models .

How is PTPRE expression regulated in normal and pathological conditions?

PTPRE expression is regulated through multiple mechanisms including transcriptional control, post-transcriptional regulation by microRNAs, and epigenetic modifications. In normal tissues, PTPRE expression shows tissue-specific patterns with relatively low expression in non-transformed mammary gland but upregulation during pregnancy and mammary gland regression . This suggests hormonal regulation of PTPRE expression during normal physiological processes.

In pathological conditions, particularly cancer, PTPRE expression can be dysregulated through various mechanisms. For example, in breast cancer, membrane-bound PTPRE is highly expressed in c-neu and v-Ha-ras induced mammary tumors in mice, but not in those initiated by c-myc or int-2. This Ras-induced upregulation of PTPRE expression appears to be mammary gland-specific and is not observed in other Ras-initiated tumors . Recent research has identified microRNA regulation of PTPRE, specifically showing that miR631 negatively regulates PTPRE expression in etoposide-resistant retinoblastoma cells. Overexpression of miR631 results in significantly decreased PTPRE protein levels, demonstrating an important post-transcriptional regulatory mechanism .

Additionally, the long non-coding RNA PTPRE-AS1 has been identified as a positive regulator of PTPRE expression. PTPRE-AS1 binds to WDR5 and mediates H3 lysine 4 trimethylation of the PTPRE promoter region, thereby epigenetically activating PTPRE gene expression . This epigenetic regulation represents an important mechanism controlling PTPRE levels in both normal and pathological conditions.

What experimental approaches are recommended for studying PTPRE expression?

When investigating PTPRE expression, researchers should employ multiple complementary approaches to obtain comprehensive and reliable data. For mRNA expression analysis, quantitative real-time PCR (qRT-PCR) using isoform-specific primers is recommended to distinguish between membrane-bound and cytosolic forms. RNA sequencing can provide broader insights into expression patterns and potential splice variants.

For protein analysis, Western blotting using specific antibodies against PTPRE is the standard approach, as demonstrated in studies of PTPRE knockdown in retinoblastoma cell lines . Immunohistochemistry or immunofluorescence staining can be used to examine tissue-specific expression patterns and subcellular localization. When performing these analyses, appropriate controls should include tissues or cells known to express high levels of PTPRE, such as certain breast cancer cell lines or osteoclasts.

To study the regulation of PTPRE expression, reporter gene assays with the PTPRE promoter can help identify transcriptional regulators. For investigating microRNA regulation, techniques such as luciferase reporter assays with the PTPRE 3'UTR and microRNA mimics or inhibitors are valuable, as exemplified by studies on miR631 regulation of PTPRE in retinoblastoma cells . For epigenetic regulation, chromatin immunoprecipitation (ChIP) assays can be used to examine histone modifications at the PTPRE promoter, as demonstrated in studies of PTPRE-AS1-mediated epigenetic activation .

How does PTPRE modulate key signaling pathways in different cell types?

PTPRE exhibits remarkable cell type-specific functions in regulating various signaling pathways. In osteoclasts, nerve cells, and endothelial cells, PTPRE positively regulates Src family kinases by dephosphorylating the inhibitory C-terminal tyrosine residue, thereby promoting kinase activation . This mechanism is conserved across multiple cell types and represents a fundamental regulatory function of PTPRE.

In immune cells, PTPRE regulates macrophage activation and cytokine production. PTPRE represses M2 macrophage activation through inhibition of the MAPK/ERK 1/2 signaling pathway. When PTPRE is knocked down, IL-4-induced ERK 1/2 phosphorylation is enhanced, leading to increased expression of M2-associated genes . This regulatory role in macrophage polarization suggests potential implications for inflammatory diseases and cancer immunology.

What experimental approaches can be used to investigate PTPRE substrates and binding partners?

Identifying PTPRE substrates and binding partners requires a multi-faceted approach combining biochemical, proteomic, and cellular techniques. Substrate-trapping mutants represent a powerful tool for capturing transient enzyme-substrate interactions. These mutants contain substitutions in the catalytic domain (commonly C→S or D→A mutations) that render the enzyme catalytically inactive while maintaining substrate binding capability. Using these mutants in pull-down assays followed by mass spectrometry can identify potential substrates.

Co-immunoprecipitation experiments can reveal binding partners of PTPRE, while proximity-based labeling techniques such as BioID or APEX can identify proteins in close spatial proximity to PTPRE within living cells. For validating direct interactions, in vitro dephosphorylation assays using recombinant PTPRE and purified phosphorylated substrates can demonstrate direct enzymatic activity.

Functional validation of PTPRE substrates should include phosphorylation-specific antibodies to monitor changes in substrate phosphorylation status following PTPRE manipulation. Additionally, reconstitution experiments with phospho-mimetic (Y→E) or phospho-deficient (Y→F) mutants of putative substrates can help determine the functional significance of PTPRE-mediated dephosphorylation. These approaches have been successfully employed to identify and validate several PTPRE substrates, including Src family kinases, insulin receptor, and components of the MAPK pathway .

How does PTPRE contribute to cancer progression and therapeutic resistance?

PTPRE plays complex and context-dependent roles in cancer biology. In breast cancer, memPTPRE expression is upregulated in c-neu and v-Ha-ras induced mammary tumors, and this upregulation is specific to mammary tissue . PTPRE contributes to breast cancer cell proliferation and survival by forming a positive feedback loop with EGFR and ERK1/2 signaling. In this context, PTPRE appears to function as a tumor-promoting factor.

In retinoblastoma, recent research has revealed a critical role for PTPRE in therapeutic resistance. Etoposide-resistant retinoblastoma cell lines exhibit high endogenous PTPRE expression levels. Knockdown of PTPRE in these resistant cells results in significantly decreased cell viability and proliferation rates, along with increased apoptosis . This apoptosis is caspase-dependent, as demonstrated by experiments using the broad-spectrum caspase inhibitor Boc-D-Fmk, which reduced apoptosis in PTPRE-depleted cells .

Importantly, PTPRE depletion contributes to re-sensitization of etoposide-resistant retinoblastoma cells to etoposide treatment. Treatment of PTPRE-depleted etoposide-resistant retinoblastoma cell lines with etoposide results in significantly decreased cell viability compared to controls . This finding suggests that PTPRE may be a potential therapeutic target for overcoming chemoresistance in retinoblastoma and potentially other cancers.

What role does PTPRE play in inflammatory and immune-related conditions?

PTPRE is implicated in various inflammatory and immune-related processes. In mast cells, PTPRE regulates FcεRI-induced activation and granule release. PTPRE-deficient mast cells exhibit enhanced Ca2+ mobilization, JNK and p38 activation, and increased degranulation and cytokine production in response to IgE stimulation . This suggests that PTPRE normally functions as a negative regulator of mast cell activation.

In macrophages, PTPRE modulates activation and cytokine production. PTPRE-deficient macrophages show reduced TNFα production and enhanced IL-10 production in response to lipopolysaccharide challenge . Additionally, PTPRE represses M2 macrophage activation by inhibiting IL-4-induced ERK 1/2 phosphorylation. When PTPRE expression is reduced, M2-associated gene expression is enhanced, indicating that PTPRE normally suppresses the M2 phenotype .

The long non-coding RNA PTPRE-AS1, which regulates PTPRE expression, has been implicated in inflammatory diseases. In models of allergic inflammation and colitis, PTPRE-AS1 deficiency leads to decreased PTPRE expression and exacerbated inflammatory responses . Lung sections from PTPRE-AS1 knockout mice exhibit significantly lower levels of PTPRE expression compared to wild-type mice, along with increased recruitment of inflammatory cells and enhanced expression of M2 macrophage markers . These findings highlight the importance of the PTPRE-AS1/PTPRE axis in regulating inflammatory responses and suggest potential therapeutic implications for inflammatory diseases.

What are the recommended approaches for generating and validating recombinant human PTPRE?

For purification, affinity tags such as His-tag or GST can facilitate initial capture, followed by additional chromatography steps such as ion exchange or size exclusion to achieve high purity. When expressing the membrane-bound form, detergent solubilization or nanodisc incorporation may be necessary to maintain proper folding and activity of the transmembrane regions.

Validation of recombinant PTPRE should include:

• SDS-PAGE and Western blotting to confirm protein size and identity

• Mass spectrometry to verify sequence integrity

• Enzymatic activity assays using artificial substrates like para-nitrophenyl phosphate (pNPP) or physiological substrates like phosphorylated peptides derived from known PTPRE substrates

• Circular dichroism or other spectroscopic techniques to assess proper folding

• Thermal shift assays to evaluate protein stability

When working with PTPRE, it is crucial to include appropriate controls such as catalytically inactive mutants (e.g., C→S mutation in the active site) to distinguish between specific enzymatic activity and non-specific effects.

What experimental models are most suitable for investigating PTPRE function?

Selection of appropriate experimental models is critical for meaningful investigation of PTPRE function. Cell culture models should be chosen based on the specific aspect of PTPRE biology under investigation. For studying PTPRE in cancer, relevant cell lines include breast cancer cells for investigating PTPRE's role in EGFR signaling and retinoblastoma cell lines for examining chemoresistance mechanisms . For immune function studies, primary macrophages, mast cells, or established immune cell lines can be used .

Genetic manipulation approaches include siRNA or shRNA for transient or stable knockdown, as demonstrated in studies of PTPRE in retinoblastoma cells . CRISPR-Cas9 technology enables complete knockout or precise editing of PTPRE. For overexpression studies, careful consideration of the specific PTPRE isoform is essential, as membrane-bound and cytosolic forms may exert different effects.

Animal models provide valuable insights into PTPRE function in vivo. PTPRE knockout mice have been used to study PTPRE's role in various physiological and pathological processes. These models have revealed the importance of PTPRE in osteoclast function, macrophage activation, and inflammatory responses . PTPRE-AS1 knockout mice have also been generated to investigate the regulatory role of this long non-coding RNA on PTPRE expression and function in inflammatory diseases .

When designing experiments using these models, considerations should include:

• Selection of appropriate readouts based on known PTPRE functions in the specific biological context

• Inclusion of relevant controls, including wild-type or scrambled siRNA controls

• Validation of PTPRE manipulation using both mRNA and protein analyses

• Consideration of potential compensatory mechanisms, particularly in knockout models

How can PTPRE be targeted for therapeutic purposes in cancer and inflammatory diseases?

PTPRE represents a promising therapeutic target based on its roles in cancer progression, chemoresistance, and inflammatory responses. Several approaches for targeting PTPRE can be considered:

For direct inhibition of PTPRE enzymatic activity, small molecule inhibitors targeting the catalytic site could be developed. While achieving specificity is challenging due to the conserved nature of PTP catalytic domains, focusing on unique structural features of PTPRE might yield selective inhibitors. High-throughput screening of compound libraries against recombinant PTPRE can identify lead compounds that can then be optimized for potency, selectivity, and pharmacokinetic properties.

RNA interference-based approaches offer another strategy. siRNA or shRNA targeting PTPRE has shown efficacy in preclinical models, as demonstrated in studies of etoposide-resistant retinoblastoma where PTPRE knockdown re-sensitized resistant cells to chemotherapy . For clinical translation, delivery systems such as lipid nanoparticles or aptamer-conjugated carriers could enhance targeting to specific tissues.

Targeting PTPRE expression through modulation of its regulatory mechanisms represents an innovative approach. For instance, miR631 mimics could be employed to downregulate PTPRE in contexts where its expression promotes disease, such as chemoresistant retinoblastoma . Similarly, targeting the PTPRE-AS1/WDR5 interaction could modulate PTPRE expression in inflammatory conditions .

In designing therapeutic strategies, the context-dependent roles of PTPRE must be carefully considered. PTPRE inhibition might be beneficial in certain cancers and inflammatory conditions but potentially detrimental in others, necessitating a thorough understanding of PTPRE function in the specific disease context.

What methodologies are recommended for screening potential PTPRE inhibitors?

Development of effective PTPRE inhibitors requires a systematic screening approach combined with rigorous validation. Primary screening should begin with in vitro enzymatic assays using purified recombinant PTPRE and suitable substrates such as para-nitrophenyl phosphate (pNPP) or phosphopeptides derived from physiological substrates. High-throughput formats in 384- or 1536-well plates can enable efficient screening of large compound libraries.

Counter-screening against related phosphatases is essential to assess selectivity. A panel including other receptor-type PTPs (e.g., PTPRA, PTPRB) and cytosolic PTPs should be used to identify compounds with preferential activity against PTPRE. Surface plasmon resonance or isothermal titration calorimetry can provide detailed binding kinetics and thermodynamics for promising compounds.

Cellular validation represents a critical step in the screening pipeline. Candidate inhibitors should be tested in relevant cell models expressing PTPRE, such as breast cancer or retinoblastoma cell lines. Readouts should include:

• Phosphorylation status of known PTPRE substrates (e.g., Src family kinases)

• Activity of downstream signaling pathways (e.g., MAPK/ERK)

• Functional outcomes such as proliferation, apoptosis, or specific cellular responses

Advanced validation should include target engagement studies using cellular thermal shift assays (CETSA) or related techniques to confirm binding of inhibitors to PTPRE in cells. For promising candidates, pharmacokinetic and toxicity studies in appropriate animal models would be required prior to clinical development.

What are the unresolved questions and emerging areas in PTPRE research?

Despite significant advances in understanding PTPRE biology, several key questions remain unresolved. The molecular basis for the divergent regulation of receptor tyrosine kinase signaling by PTPRE in normal versus cancer cells remains poorly understood. While PTPRE inhibits insulin receptor and PDGFB signaling in normal cells, it positively regulates EGFR signaling in cancer cells . Elucidating the mechanisms underlying this context-dependent signaling regulation could provide important insights for therapeutic targeting.

The interplay between different PTPRE isoforms and their specific functions requires further investigation. While membrane-bound and cytosolic forms have been characterized to some extent, their relative contributions to various physiological and pathological processes remain to be fully defined. Advanced techniques such as isoform-specific knockdown or knockout models could help address these questions.

Emerging areas in PTPRE research include:

• The role of PTPRE in tumor microenvironment and cancer immunity, given its functions in macrophage polarization and cytokine production

• The potential of PTPRE as a biomarker for predicting therapeutic response, particularly in the context of chemoresistance

• The involvement of PTPRE in metabolic regulation, suggested by its interaction with insulin receptor signaling

• The broader implications of the PTPRE-AS1/PTPRE regulatory axis in various disease contexts

Understanding these aspects of PTPRE biology will not only advance our fundamental knowledge but also inform the development of more effective therapeutic strategies targeting this phosphatase.

What technological advances are needed to address current limitations in PTPRE research?

Advancing PTPRE research requires overcoming several methodological challenges through technological innovation. Improved tools for studying protein-protein interactions in living cells would enhance our understanding of PTPRE's dynamic interactions with substrates and binding partners. Techniques such as bioluminescence resonance energy transfer (BRET), fluorescence resonance energy transfer (FRET), or split-luciferase complementation assays could be optimized for PTPRE studies.

Development of highly selective probes for monitoring PTPRE activity in live cells would represent a significant advance. Activity-based probes that become fluorescent or change spectral properties upon dephosphorylation by PTPRE would enable real-time visualization of PTPRE activity in various cellular compartments and contexts.

For in vivo studies, conditional and tissue-specific PTPRE knockout or knockin models would provide more nuanced insights into PTPRE function than conventional global knockout approaches. CRISPR-Cas9-based approaches for generating such models in diverse organisms could expand our understanding of PTPRE biology across species.

High-resolution structural analysis of full-length PTPRE, particularly the membrane-bound form, remains challenging due to the presence of transmembrane domains. Advances in cryo-electron microscopy or innovative crystallization techniques for membrane proteins could overcome these limitations and provide valuable structural insights to guide inhibitor design.

Finally, computational approaches integrating multi-omics data (genomics, transcriptomics, proteomics, phosphoproteomics) could help identify PTPRE-regulated networks and predict context-dependent functions across different cell types and disease states.